COYOTE

About COYOTE

Coyote Bioscience, founded in 2009, is a high-tech enterprise focused on developing and manufacturing point-of-care testing (POCT) molecular diagnostic solutions. The company provides fully automated, integrated, and rapid molecular diagnostic systems, including instruments and reagents, designed for decentralized settings.

The company's core technology revolves around its FlashDetect™ platform, which utilizes fully enclosed all-in-one cartridges for rapid nucleic acid extraction and qPCR analysis, delivering results in as little as 10-25 minutes. This platform includes various instruments like the FlashDetect™ Nano, Mini8, Flash20, and Flash48, offering scalable solutions for both individual tests and high-throughput screening. These systems are designed to be portable and user-friendly, reducing reliance on specialized healthcare professionals. Coyote Bioscience serves a wide range of clients, including medical centers, hospitals, clinics, transportation hubs, and provides solutions for veterinary and food safety applications.

Headquartered in Beijing, China, Coyote Bioscience has established a global presence with R&D centers in Beijing and Silicon Valley, USA, and production facilities in Beijing, Tianjin, and Jiangsu. The company has a significant history of technological development, including creating a portable real-time qPCR analyzer in 2013 and receiving its first Class III Medical Device License in China in 2016. Its products have been deployed globally to help combat epidemics such as the 2014 Ebola outbreak and the 2020 COVID-19 pandemic. Coyote has obtained numerous certifications, including CE IVD, China NMPA, and ISO 13485, and its products are available in over 65 countries.